{"id":"ap-12009-10-m","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"AP 12009 targets TGF-β2 mRNA, reducing production of this immunosuppressive cytokine in the tumor microenvironment. By decreasing TGF-β2 levels, the drug aims to relieve immune suppression and enhance the body's natural anti-tumor immune response. This mechanism is particularly relevant in cancers where TGF-β2 contributes to immune evasion and tumor progression.","oneSentence":"AP 12009 is an antisense oligonucleotide that inhibits transforming growth factor-beta 2 (TGF-β2) expression to reduce immunosuppression and promote anti-tumor immunity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:56:55.726Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Glioblastoma"},{"name":"Pancreatic cancer"}]},"trialDetails":[{"nctId":"NCT00761280","phase":"PHASE3","title":"Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma","status":"TERMINATED","sponsor":"Isarna Therapeutics GmbH","startDate":"2008-12","conditions":"Anaplastic Astrocytoma, Glioblastoma","enrollment":27},{"nctId":"NCT00431561","phase":"PHASE2","title":"Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma","status":"COMPLETED","sponsor":"Isarna Therapeutics GmbH","startDate":"2003-04","conditions":"Glioblastoma, Anaplastic Astrocytoma","enrollment":141}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AP 12009 10 µM","genericName":"AP 12009 10 µM","companyName":"Isarna Therapeutics GmbH","companyId":"isarna-therapeutics-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AP 12009 is an antisense oligonucleotide that inhibits transforming growth factor-beta 2 (TGF-β2) expression to reduce immunosuppression and promote anti-tumor immunity. Used for Glioblastoma, Pancreatic cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}